Work

Advances in Immunotherapy for Breast Cancer

Year: 2026

Type: article

Abstract: Immunotherapy has transformed the treatment of a variety of malignancies, including breast cancer. Given the unmet clinical need, immunotherapy was first studied in advanced-stage, triple-negative breast cancer (TNBC). The anti-PD-1 agent pembrolizumab plus chemotherapy is approved for both advanced and early TNBC, and data from randomized phase 3 trials in high-risk, early-stage, hormone receptor-positive breast cancer have demonstrated promising efficacy. Ongoing trials aim to identify the most appropriate patients for treatment, amount and timing of immunotherapy needed for optimal outcomes, and ideal combination of therapies to maximize survival while minimizing toxicity. The future of immunotherapy in breast cancer will continue to evolve with the advent of novel immunologic agents. In this review, we highlight pivotal trials that have informed current practice and ongoing trials that may inform the therapeutic landscape in the coming years.

Source: ONCOLOGY

DOI: 10.46883/2026.25921061

Authors: Sarah Poland, Matheus de Oliveira Andrade, Rita Nanda

Institutions: University of Chicago, Centro Universitário das Américas (FAM) - São Paulo

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute